Patient with perianal fistulizing Crohn's disease and failure to intensified risankizumab treatment.

No direct evidence for the management of perianal fistulizing Crohn's disease following risankizumab treatment failure was identified. Alternative therapies, such as ustekinumab or vedolizumab, may be considered based on indirect evidence, but further research is necessary to establish specific guidelines.